IL13 and Eczematoid dermatitis: Experimental studies demonstrate its capacity to suppress nuclear factor‐κB‐mediated inflammatory pathways (Hayashi et al. 2012), reducing key cytokines such as IL‐4 and IL‐13 (Hayashi et al. 2012; Mabalirajan et al. 2009), which drive eczema pathogenesis.